EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

12 Mar 2025 08:00:26 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

10 Mar 2025 09:14:36 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

03 Mar 2025 16:23:25 By Nasdaq GlobeNewswire

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

18 Feb 2025 08:55:56 By Nasdaq GlobeNewswire

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

07 Feb 2025 08:06:54 By Nasdaq GlobeNewswire

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

16 Jan 2025 08:00:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

14 Jan 2025 07:30:34 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

13 Jan 2025 09:27:39 By Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

08 Jan 2025 07:45:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

08 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

16 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06 Nov 2024 16:49:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

06 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

04 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

23 Oct 2024 07:30:55 By Nasdaq GlobeNewswire

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

08 Oct 2024 17:32:28 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

02 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

26 Sep 2024 08:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

25 Sep 2024 07:07:16 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

13 Sep 2024 06:45:00 By Nasdaq GlobeNewswire